Dr Davidson Ateh, BioMoti CEO, discusses BioMoti’s technology, achievements and plans in an interview with Dr Fintan Walton for PharmaTelevision. Please click here to watch the interview

Earlier this year, Dr Davidson Ateh, CEO, welcomed Philip Hemme and Joachim Eeckhout from LaBiotech Tour to Queen Mary University of London’s QMB Innovation Centre and Blizard Institute during their documentary tour of the UK’s biotech clusters. LaBiotech Tour is the first collection of documentary films about the world’s most vibrant biotech ecosystems. Find out […]

Dr Davidson Ateh, CEO, discusses efforts to bring BioMoti to an international audience in this winter issue of the QMB Newsletter. The article reviews three trips to the US under UKTI support and a couple to China organised by the Open Innovation unit at the University of Bradford with sponsorship from Yorkshire Cancer Research and AstraZeneca. […]

Dr Davidson Ateh, CEO, discusses BioMoti’s Oncojan™ intracellular drug delivery technology for cancer treatment with Tom Mulligan, Editor, in the May/June 2013 edition of sp2 Inter-Active. The article explores the origins of BioMoti, it’s technological capabilities, lead ovarian cancer candidate, business model, growth plans and the current context for early stage UK biotech companies. Click for article: BioMoti […]

Dr Davidson Ateh, CEO of BioMoti and researcher at Queen Mary, University of London is profiled in the autumn edition of BBSRC Business magazine. In the interview Dr Ateh discusses the origins and aims of BioMoti and his personal journey towards technology entrepreneurship. Read the interview on the BBSRC website.

Dr Davidson Ateh, researcher at Queen Mary, University of London and Royal Society of Edinburgh/BBSRC Enterprise Fellow is featured on PharmaTelevision panel discussion: ‘Early Stage Spin Outs and the Road to Success’. In the programme presented by Dr Fintan Walton (CEO and Founder of PharmaVentures), Dr Ateh discusses the challenges new technology start-ups face in […]